Blog
RSS FeedPosted by Michael Wonder on 02 Mar 2020
Coronavirus triggers national medical stockpile as COVID-19 threat intensifies
29 February 2020 - It could be any warehouse in Australia. In fact, you may travel past it every day ...
Posted by Michael Wonder on 26 Feb 2020
Independent review of the reforms to the therapeutic goods advertising framework to commence
26 February 2020 - The independent review of the advertising reforms has now commenced, and is being led by Ms Rosemary ...
Posted by Michael Wonder on 25 Feb 2020
Brexit - implications for therapeutic goods in Australia
25 February 2020 - A transition period is in effect until the end of 2020 while the UK and EU negotiate ...
Posted by Michael Wonder on 19 Feb 2020
Frustration as life-saving EpiPens sit in warehouses, pharmacists out of stock
19 February 2020 - The peak body for Australians with severe allergies is calling on pharmacists to stock up on ...
Posted by Michael Wonder on 12 Feb 2020
Australia's biotech innovations heading offshore, prompting calls for greater funding to bring them to market
11 February 2020 - The demand on the health sector has never been more evident, as the world scrambles to ...
Posted by Michael Wonder on 20 Jan 2020
Fees and charges proposal 2020-21
20 January 2020 - The TGA is undertaking a consultation through its website to seek stakeholder's views on TGA’s proposed fees ...
Posted by Michael Wonder on 20 Jan 2020
New science strategy prepares regulatory scientists for the future
20 January 2020 - The Health Products Regulation Group in the Department of Health has published a new regulatory science ...
Posted by Michael Wonder on 14 Jan 2020
TGA - 2019 in review
14 January 2020 - According to the TGA, it approved 34 new chemical entities in 2019. ...
Posted by Michael Wonder on 03 Dec 2019
EpiPen Jr
2 December 2019 - Due to the critical nature of the ongoing EpiPen Jr shortage, the TGA is allowing one ...
Posted by Michael Wonder on 25 Nov 2019
Acalabrutinib receives TGA approval for CLL and SLL cancers
25 November 2019 - The Therapeutic Goods Administration has approved the use of acalabrutinib (Calquence) for the treatment of patients ...
Posted by Michael Wonder on 21 Nov 2019
FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukaemia
21 November 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, ...
Posted by Michael Wonder on 11 Nov 2019
TGA approved terminology for therapeutic goods
11 November 2019 - The Therapeutic Goods Administration develops and maintains approved terminology to ensure the accuracy and consistency of ...
Posted by Michael Wonder on 24 Oct 2019
Proposed new classification rule for medical devices that administer medicines or biologicals by inhalation
24 October 2019 - The TGA thanks respondents who provided a submission in response to the public consultation paper Proposed new ...
Posted by Michael Wonder on 21 Oct 2019
Annual performance statistics report: July 2018 to June 2019
21 October 2019 - At 30 June 2019 there were 88,788 therapeutic goods on the ARTG, including 31,987 new products added ...
Posted by Michael Wonder on 14 Oct 2019
STA to market sarcoma drug in Australia, New Zealand and SE Asia following license deal
14 October 2019 - Specialised Therapeutics now filing for TGA approval. ...